Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Bacteria-Based Biosensor Detects Zinc Deficiency

By LabMedica International staff writers
Posted on 14 Sep 2015
A series of genetic engineering steps led to the development of a bacterial biosensor capable of visually distinguishing levels of zinc, a critical micronutrient.

Micronutrient deficiencies, including zinc deficiency, are responsible for hundreds of thousands of deaths annually. More...
A key obstacle to allocating scarce treatment resources is the ability to measure population blood micronutrient status inexpensively and quickly enough to identify those who most need treatment.

To overcome this obstacle a team of molecular microbiologists at the Georgia Institute of Technology (Atlanta, USA) developed a novel approach for inexpensive screening of micronutrients, with zinc being the test case.

Towards this end, the investigators genetically engineered a strain of Escherichia coli to produce different colored pigments (violacein, lycopene, and beta-carotene) in response to different extracellular zinc levels. Genes for the pigments were taken from other organisms and inserted into the E. coli on a plasmid. The red and orange colors, lycopene and beta-carotene, were produced by genes taken from Pantoea anantis, a plant pathogen. The purple color, violacein, came from a soil bacterium.

Obtaining discrete color states in the carotenoid pathway required precise engineering of the E. coli's metabolism to prevent a reaction at low zinc concentrations but allow complete reaction at higher concentrations, and all under the constraints of the bacterium's natural regulator limitations. A combination of gene dosage, post-transcriptional, and post-translational regulation was necessary to allow visible color change over physiologically relevant ranges representing a small fraction of the regulator’s dynamic response range, with further tuning possible by modulation of precursor availability.

In practice, a pellet of the engineered bacteria was mixed with the plasma from a human subject. The E. coli multiplied, producing the color corresponding to the level of zinc in the sample. Purple corresponded to dangerously low levels, while red indicated borderline levels, and orange normal levels. The color was readily visible without any diagnostic or other electronic equipment.

"We think this is just enough technology to meet the needs," said Dr. Mark Styczynski, assistant professor of chemical and bio-molecular engineering at the Georgia Institute of Technology. "Information we can provide could one day help nutritional epidemiologists and non-governmental organizations determine the populations of people that may need interventions to address nutritional deficiencies."

"The general idea of bio-sensing is certainly out there, but we have taken the step of developing a system that does not require equipment in the field," said Dr. Styczynski. "We believe this will work well in low-resource areas. This is a convincing proof-of-principle, and we hope to begin the translational aspects of this system based on what we have already shown. It is a matter now of reducing this to practice for something that will ultimately be useful."

The novel assay for zinc deficiency was described in a paper published in the September 2015 issue of the journal Metabolic Engineering.

Related Links:

Georgia Institute of Technology



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.